As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients.
The development of chimeric antigen receptor T cell (CAR-T cell) therapiessuch as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)and their success in combating hematological malignancies, has paved the way for a surge in investment in CGT, especially adoptive cellular transfer (ACT), in oncology. While in the beginning, we were somewhat limited to CAR-T monotherapies anchored in single antigen targets for CD19-expressing lymphomas and leukemias, research has grown to include expanded and multi-targeting modalities, including additional adoptive cell therapy immune cell vehicles (e.g. NK cells, macrophages, dendritic cells, CD 4+ T cells, etc.). Therefore, it is likely CAR-T cells may be used as both monotherapy, or in combination with novel agents.
Estimates as of February 2020 suggest there are more than 1,000 CGT trials globally, with nearly 600 of those in oncology. Whats more, recent market intelligence projects the global CGT market will continue to rise at a compound annual growth rate of 36.25 percent between 2019 and 2025. The investment in oncology emphasizes the importance of developing innovative and accelerated ways to deliver CGT trials and address the challenges of scaling to commercialization. As such, the demand for understanding how to solve these challenges will continue to increase over the next decade.
The success of CGT has transformed the delivery of clinical trial services, requiring the design of new workflows, processes, and tools to address the nuances and complexities of how CGT trials are executed compared to traditional trials. As the industry evolves, the next generation of adoptive cellular transfer products will move closer to becoming a front-line treatment, as opposed to being limited to relapsed or refractory patients, and will have improved safety and durability of response. Developing improved investigational products requires the use of laboratory services to better identify targets and biomarkers, such as advancing polymerase chain reaction (PCR) and liquid biopsy techniques.
Here, we outline the challenges in designing and executing oncology CGT clinical trials and potential solutions to those complexities.
Challenges in designing and executing CGT clinical trials
Cell therapies are living medicines, with many being autologous, requiring each patient sample to have its own process. This personalization creates a more complex development cycle than other biologic drugs. One of the main challenges in this approach is developing well-defined characteristics or attributes (i.e., cell phenotype of functional measurements) that are well correlated with outcomes for these investigational products, as there are many causes of variability. For example, there may be differences in cells from donor to donor, which can make it difficult to determine which factors drive efficacy and safety. Notably, with CAR-T therapies, significant side effects include cytokine release syndrome (caused by the production of a large number of inflammatory molecules by CAR-T cells) and neurotoxicity, both of which are related to therapeutic efficacy. New characteristic safety profiles could emerge, which need specific considerations on how to manage patients.
Moreover, as biotech companies start to move toward solid tumor targets, the treatment of patients with advanced solid tumors has become more dependent on tissue biomarkers to help guide management decisions. As a result, the ability to obtain tissue for the production or expansion of cell therapies adds another burden. Further, targeted therapies are associated with superior clinical outcomes, but to obtain updated biomarkers and targets, large biopsy specimens are often needed. This is not always feasible, either because lesions are not safely accessible to a surgeon or an interventional radiologist, or because the patient declines further invasive procedures.
Allogeneic therapies, or those using cells from healthy donors, may avoid some complexities of modifying a patients own cells. For example, Gracell Biotechnologies recently presented preliminary results of a first-in-human, universal CAR-T therapy, GC027which targets CD7 on malignant T cellsfor treating adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia. The ability to produce hundreds of viable cells for multiple infusions can overcome issues related to the time it takes to manufacture T-cells, costs to generate a product for each patient, failures in the ability to generate a product from a patients immune cells, and the heterogeneity of T-cell products. However, allogeneic approaches will need to circumnavigate challenges in tissue-matching, which means that human leukocyte antigen typing becomes important in many cases, possibly limiting the target population.
Gene editing and other engineered products, such as T-cell receptor (TCR)-engineered T cells, to treat cancer, are entering into safety and feasibility trials. For example, the first clinical trial using CRISPR-Cas 9 editing to engineer T cells in patients with refractory cancer launched in the fall of 2019. These experimental technologies will raise similar challenges as they move forward through early phase clinical trials.
Conclusion
Over the next 10 years, we will continue to witness significant advances and excitement as CGT saves the lives of patients. First, the industry will conquer the challenges created by the tumor microenvironment, opening opportunities to successfully tackle a broader range of solid tumors. Second, new strategies will emerge to improve the manufacturing and delivery of autologous and allogeneic therapies, improving cost-efficiency. These future advances will be assisted by enhanced diagnostic assays and other tests to improve our understanding of targeting and treating cancer.
Originally posted here:
Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials - Clinical OMICs News
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]